Lion TCR, a Singapore-based clinical-stage biotechnology company with backing from Chinese investors, has entered into a partnership with U.S. firm MaxCyte Inc. to harness mRNA technology for the development of TCR-T therapies. These therapies are aimed at treating solid tumors and virus-related diseases. The collaboration will enable Lion to utilize MaxCyte’s Flow Electroporation technology and ExPERT platform, enhancing its clinical plans and commercial applications.
Under the terms of the agreement, Lion will pay MaxCyte an undisclosed sum in licensing fees and project income for non-exclusive clinical and commercial rights to MaxCyte’s Flow Electroporation technology and ExPERT platform. MaxCyte’s ExPERT product portfolio represents the next-generation, clinically validated mRNA electroporation technology used for complex and scalable cell engineering. Known for its high transfection efficiency, seamless scalability, and advanced performance, the ExPERT platform delivers premium results for next-generation biological and cell therapies.- Flcube.com
